Resistance Profiling Using Functional Imaging and Next Generation Sequencing in Refractory Gastrointestinal Stomal Tumors (GIST)

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversität Duisburg-Essen

About this trial

Gastrointestinal stromal tumors (GIST) are the most common malignant sarcomas of the gastrointestinal tract. Inhibitors of the mutated driver proteins KIT and PDGFRA can temporarily control disseminated GIST disease but cannot cure it. Recently, the investigators were able to elucidate the two main resistance mechanisms-the coexistence of ATP-binding pocket (AP) and activation loop (AL) mutations, as well as AP/AL combination mutations. Determining these resistance factors requires methods that are not yet established in routine clinical practice. The investigators hypothesize that identifying these factors and creating resistance profiles in the context of the anatomical location of metastatic lesions can open up new, clinically relevant therapeutic options, including local therapies. The aim of this project is to evaluate the practicability of these methods in everyday clinical use. An AI-supported image analysis and specialized molecular methods will be combined into a comprehensive resistance profile and will be provided to the treating physicians to potentially guide treatment decisions.

Eligibility criteria

Qualifiers

Advanced gastrointestinal stromal tumors history of exposure and progression or intolerance to imatinib, sunitinib, regorafenib and ripretinib

Clinical indication for PET-CT and tumor biopsy (optional) (sarcoma center tumorboard protocol)

Age 18 years and older

FFPE tumor tissue available

Disqualifiers

contraindication for systemic TKI treatment

contraindication for contrast-enhanced both CT and MRI imaging.

GIST without KIT or PDGFRA mutations

pregnant or breastfeeding women

Trial design

Treatments tested in this trial

  • Generation of a comprehensive and single-lesion resistance profile

Treatment groups

No treatment groups listed

Sponsors and collaborators

Universität Duisburg-Essen

Lead sponsor

University Hospital Münster, Insitute of Pathology

Collaborator

University Hospital Schleswig-Holstein

Collaborator